Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

In the evolving landscape of pharmaceutical production, fill-finish contract manufacturing has become a crucial area of focus ...

The global stem cell therapy market is poised for remarkable growth, with revenues projected to escalate from USD 394.50 million in 2024 to USD 2,612.92 million by 2033, reflecting a compelling ...

Pharma Lessons has added two new bonus modules to the popular Good Manufacturing Practice Training. The new modules are already available to all currently enrolled users.The first module covers the ...

The report, released at Global Pharmaceutical Quality Summit in Mumbai, draws comparison of incidences of ‘official action ...

India’s pharmaceutical sector, the world’s largest supplier of generic medicines, is poised for a new era of growth with ...

TCS is currently testing the lower boundary of a falling channel while holding above the 100-week EMA and the long-term ascending trendline support. This confluence suggests a potential rebound ...

announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a certificate of GMP ...

Quality Power IPO subscription status: Quality Power Electrical Equipments' initial public offering (IPO), which opened for public subscription on February 14, 2025, is set to conclude today, February ...

The grey market premium (GMP) of Quality Power has seen a sharp correction on the back of dull bidding for the issue and dented market sentiments. Last heard, the company was commanding a no grey ...